388 related articles for article (PubMed ID: 26674124)
1. Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine.
Tozuka M; Oka T; Jounai N; Egawa G; Ishii KJ; Kabashima K; Takeshita F
J Dermatol Sci; 2016 Apr; 82(1):38-45. PubMed ID: 26674124
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A Literature Analysis.
Quach HQ; Kennedy RB
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366536
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial.
Arakane R; Nakatani H; Fujisaki E; Takahama A; Ishida K; Yoshiike M; Nakayama T; Takeshita F
Vaccine; 2015 Nov; 33(46):6340-50. PubMed ID: 26431983
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
Chi RC; Rock MT; Neuzil KM
Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
8. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study.
Arakane R; Annaka R; Takahama A; Ishida K; Yoshiike M; Nakayama T; Takeshita F
Vaccine; 2015 Nov; 33(48):6650-8. PubMed ID: 26519549
[TBL] [Abstract][Full Text] [Related]
9. Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: A systematic review.
Schnyder JL; Garcia Garrido HM; De Pijper CA; Daams JG; Stijnis C; Goorhuis A; Grobusch MP
Travel Med Infect Dis; 2021; 41():102007. PubMed ID: 33711425
[TBL] [Abstract][Full Text] [Related]
10. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
[TBL] [Abstract][Full Text] [Related]
12. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
[TBL] [Abstract][Full Text] [Related]
13. Serum antibody responses after intradermal vaccination against influenza.
Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
[TBL] [Abstract][Full Text] [Related]
14. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
[TBL] [Abstract][Full Text] [Related]
16. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
17. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y
Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353
[TBL] [Abstract][Full Text] [Related]
18. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice.
Magnusson SE; Reimer JM; Karlsson KH; Lilja L; Bengtsson KL; Stertman L
Vaccine; 2013 Mar; 31(13):1725-33. PubMed ID: 23384754
[TBL] [Abstract][Full Text] [Related]
19. Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.
Liang F; Lindgren G; Lin A; Thompson EA; Ols S; Röhss J; John S; Hassett K; Yuzhakov O; Bahl K; Brito LA; Salter H; Ciaramella G; Loré K
Mol Ther; 2017 Dec; 25(12):2635-2647. PubMed ID: 28958578
[TBL] [Abstract][Full Text] [Related]
20. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.
Zhuang Y; Ma Y; Wang C; Hai L; Yan C; Zhang Y; Liu F; Cai L
J Control Release; 2012 Apr; 159(1):135-42. PubMed ID: 22226776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
